New recommendations for neoadjuvant treatment of HER2‑positive breast cancer patients

04/2017

MUDr. Dagmar Brančíková, Ph.D., MUDr. Markéta Protivánková

Interní hematologická a onkologická klinika, FN Brno

SUMMARY

Treatment of locally advanced breast cancer with HER2/neu amplification is systemic and consists of chemotherapy and receptor blockade. The neoadjuvant procedure is designed to rapidly reduce tumor mass and operability, despite the misgivings of several studies, the complete remission remains pathological (pCR) is a reliable substitute Time to progression or overall survival. In this paper we present a summary of some experience with chemotherapy regimens and HER2/neu blockers and their potential combinations. The most promising 3-year data from trial NeoSphere show a promising trend to improve progression free survival for the combination of docetaxel/trastuzumab/pertuzumab that increased pCR from 29% to 46%. In all neoadjuvant studies, the group of patients with a hormone-positive disease had less benefit from anti-HER2 blockade and chemotherapy, but this procedure has yet to be verified as the best.

KEY WORDS

neoadjuvant, HER positive breast cancer, trastuzumab, pertuzumab